Exhibit 99.1 TELA Bio Reports First Quarter 2024 Financial Results MALVERN, PA, May 9, 2024 -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions today reported financial results for the first quarter ended March 31, 2024. Recent Highlights · Reported revenue of $16.6 million in the first quarter, representing growth of 39% over the prior year period of 2023; · Delivered the 13th consecutive quarter of at least 35% ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39130 TELA Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 45-5320061 (State or other ju ...

TELA Bio, Inc. (NASDAQ:TELA) Q4 2023 Earnings Conference Call March 21, 2024 4:30 PM ET Company Participants Louisa Smith - Vice President, Gilmartin Group Antony Koblish - Co-Founder, President and Chief Executive Officer Roberto Cuca - Chief Operating Officer and Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Markets Caitlin Cronin - Canaccord Genuity Michael Sarcone - Jefferies David Turkaly - JMP Securities Operator Good afternoon ladies and gentlemen and welco ...

Exhibit 99.1 TELA Bio Achieves Record Fourth Quarter and Full Year 2023 Revenues and Reports Complete Financial Results MALVERN, PA, March 21, 2024 -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy, today reported financial results for the fourth quarter and full year ended December 31, 2023. Recent High ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____ to ____ Commission File Number: 001-39130 TELA Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 45-5320061 ...

TELA Bio, Inc. (NASDAQ:TELA) Q3 2023 Earnings Call Transcript November 9, 2023 4:30 PM ET Company Participants Greg Chodaczek - Gilmartin Group Tony Koblish - President and Chief Executive Officer Roberto Cuca - Chief Operating Officer and Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Markets Caitlin Cronin - Canaccord Genuity Matthew OÂ’Brien - Piper Sandler Michael Sarcone - Jefferies Dave Turkaly - JMP Securities Operator Good day and thank you for standing by, ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____ to ____ Commission File Number: 001-39130 TELA Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 45-5320061 (Sta ...

TELA Bio, Inc. (NASDAQ:TELA) Q2 2023 Earnings Conference Call August 9, 2023 4:30 PM ET Company Participants Louisa Smith – Gilmartin Group Tony Koblish – President and Chief Executive Officer Roberto Cuca – Chief Operating Officer and Chief Financial Officer Conference Call Participants Michael Sarcone – Jefferies Frank Takkinen – Lake Street Capital Markets David Turkaly – JMP Securities Operator Good afternoon, ladies and gentlemen, and welcome to the TELA Bio Second Quarter 2023 Earnings Conference Call ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____ to ____ Commission File Number: 001-39130 TELA Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 45-5320061 (St ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39130 TELA Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 45-5320061 (State or other ju ...